| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CRO服务(元) | 8,555,182.02 | - | 7,620,771.42 |
| 靶点及因子类蛋白(元) | 41,846,420.14 | 64,593,303.09 | 29,129,077.19 |
| 酶及试剂(元) | 18,474,457.18 | 41,719,193.17 | 19,769,434.84 |
| 重组抗体(元) | 1,928,029.50 | 5,241,486.54 | 3,086,286.36 |
| 技术服务(元) | - | 15,848,872.88 | - |
| 营业成本(元) | |||
| CRO服务(元) | 8,155,952.53 | - | 5,101,127.77 |
| 靶点及因子类蛋白(元) | 9,452,918.98 | 18,305,939.13 | 8,608,361.97 |
| 酶及试剂(元) | 6,483,222.66 | 15,895,037.38 | 7,640,946.91 |
| 重组抗体(元) | 344,766.55 | 1,200,478.36 | 480,817.96 |
| 技术服务(元) | - | 12,492,289.84 | - |
| 毛利(元) | |||
| CRO服务(元) | 399,229.49 | - | 2,519,643.65 |
| 靶点及因子类蛋白(元) | 32,393,501.16 | 46,287,363.96 | 20,520,715.22 |
| 酶及试剂(元) | 11,991,234.52 | 25,824,155.79 | 12,128,487.93 |
| 重组抗体(元) | 1,583,262.95 | 4,041,008.18 | 2,605,468.40 |
| 技术服务(元) | - | 3,356,583.04 | - |
| 毛利率(%) | |||
| CRO服务(%) | 4.67 | - | 33.06 |
| 靶点及因子类蛋白(%) | 77.41 | 71.66 | 70.45 |
| 酶及试剂(%) | 64.91 | 61.90 | 61.35 |
| 重组抗体(%) | 82.12 | 77.10 | 84.42 |
| 技术服务(%) | - | 21.18 | - |
| 收入构成(%) | |||
| CRO服务(%) | 12.08 | - | 12.79 |
| 靶点及因子类蛋白(%) | 59.10 | 50.70 | 48.87 |
| 酶及试剂(%) | 26.09 | 32.75 | 33.17 |
| 重组抗体(%) | 2.72 | 4.11 | 5.18 |
| 技术服务(%) | - | 12.44 | - |
| 毛利构成(%) | |||
| CRO服务(%) | 0.86 | - | 6.67 |
| 靶点及因子类蛋白(%) | 69.86 | 58.22 | 54.32 |
| 酶及试剂(%) | 25.86 | 32.48 | 32.11 |
| 重组抗体(%) | 3.41 | 5.08 | 6.90 |
| 技术服务(%) | - | 4.22 | - |